Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

ACADIA Pharmaceuticals reports increased revenue in first-quarter 2010

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2010.

11 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Study highlights benefits of using endometrial stem cells to restore functioning of brain cells

Stem cells derived from the endometrium (uterine lining) and transplanted into the brains of laboratory mice with Parkinson's disease appear to restore functioning of brain cells damaged by the disease, according to a new study by Yale School of Medicine researchers.

7 May 2010

Mouse study may lead to new therapies for Parkinson's disease

Endometrial stem cells injected into the brains of mice with a laboratory-induced form of Parkinson's disease appeared to take over the functioning of brain cells eradicated by the disease.

7 May 2010

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.

6 May 2010

Scientists use specialized fluorescent protein to study nerve cell activity

Electrical currents are invisible to the naked eye - at least they are when they flow through metal cables. In nerve cells, however, scientists are able to make electrical signals visible. Working with fellow experts from Switzerland and Japan, scientists from the Max Planck Institute for Medical Research in Heidelberg successfully used a specialized fluorescent protein to visualize electrical activity in neurons of living mice.

6 May 2010

Making stem cells in the lab: a training program and a study

Young researchers will now be trained for the first time by the Australian Stem Cell Centre (ASCC) in scientific techniques of using and growing human induced pluripotent stem (iPS) cells in research. This training will be through StemCore iPS Cell Workshop, the ASCC's national facility for the provision of stem cells and advice.

5 May 2010

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.

4 May 2010

Moving story of a Parkinson's patient

Over 1.5 million people in the U.S. suffer from Parkinson's disease, a degenerative neurological disorder most recently brought attention to by Michael J. Fox. In his new release, "Move On with Parkinson's: An Inspirational True Story as Told by a PD Patient" (published by LuLu), author Michael Stanfield shares his struggle with Parkinson's and the medical treatments and exercise that helped reverse his symptoms.

4 May 2010

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

UCSF researchers have created the first transgenic mouse to display the earliest signs of Parkinson's disease using the genetic mutation that is known to accompany human forms of the disease.

4 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

Rigel Pharmaceuticals receives 2010 Innovators Award of Excellence

Rigel Pharmaceuticals, Inc. has been named one of the recipients of the 2010 Innovators Award of Excellence by the San Mateo County Economic Development Association. The award will be presented at the association's Innovators luncheon today at the Oracle Conference Center in Redwood City.

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

MU researcher develops test to pinpoint neurological origins of dysphagia

Muscle degeneration and confinement to a wheelchair are the hallmarks of Lou Gehrig's disease, Parkinson's, muscular dystrophy and other neurodegenerative diseases. One of the silent, and most serious, symptoms of these diseases is losing the ability to swallow.

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

ACADIA Pharmaceuticals reports increased revenue in first-quarter 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Study highlights benefits of using endometrial stem cells to restore functioning of brain cells

Mouse study may lead to new therapies for Parkinson's disease

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

Scientists use specialized fluorescent protein to study nerve cell activity

Making stem cells in the lab: a training program and a study

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Moving story of a Parkinson's patient

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

BioTime acquires ES Cell International

Rigel Pharmaceuticals receives 2010 Innovators Award of Excellence

ISTA Pharmaceuticals first-quarter net revenues up 39%

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

BioTime to acquire Singapore-based company, ES Cell International

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

MU researcher develops test to pinpoint neurological origins of dysphagia

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in